Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
EARLY_PHASE1
40 participants
INTERVENTIONAL
2025-01-31
2026-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The primary objectives of this study are to answer the following key questions:
1. The incidence of dose-limiting toxicities (DLTs) during the designated observation period.
2. The incidence and severity of adverse events (AEs) and serious adverse events (SAEs).
3. The determination of the maximum tolerated dose (MTD) or maximum administered dose (MAD).
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SEQUENTIAL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm A
Safe run-in phase and Dose Expansion phase
mRNA Neoantigen Vaccine
mRNA Neoantigen Vaccine
Adebrelimab
Adebrelimab is a programmed death-ligand 1 antibody.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
mRNA Neoantigen Vaccine
mRNA Neoantigen Vaccine
Adebrelimab
Adebrelimab is a programmed death-ligand 1 antibody.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Qualify and sufficient tumor samples for genetic testing and neoantigen analysis
* There are no EGFR and ALK gene alteration
* Eastern Cooperative Oncology Group (ECOG) score of United States: 0 or 1 point
* Estimated survival ≥ 6 months
* Qualify and sufficient blood samples for immunogenicity and biomarkers before and after treatment, of which the blood samples for genetic testing during the screening period must be free of blood transfusions, blood products and other hematopoietic stimulating factors within 7 days before collection
* Postoperative complications have recovered, or complications are lower than Clavien-Dindo complication grade 3
* There was no evidence of disease in clinical examination, chest and abdomen contrast-enhanced CT and baseline radiological evaluation of head MRI within 14 days before the first dose
* Female subjects of childbearing potential must have a serum pregnancy test within 7 days prior to the first dose with a negative result; and must be non-lactating
* Female subjects of childbearing potential and male subjects whose partners are women of childbearing potential must agree to comply with contraceptive requirements from the time of signing the informed consent form until 90 days after the end of the last treatment (see "Contraceptive methods" in Annex V for details)
Exclusion Criteria
* Any person who is not suitable for immunotherapy as assessed by the investigator
* Presence of autoimmune diseases, except for hypothyroidism due to autoimmune thyroiditis that only requires hormone replacement therapy
* Evidence of active tuberculosis infection within 1 year prior to initiation of study treatment, regardless of treatment
* Subjects with a known history of interstitial pneumonia or a high suspicion of interstitial pneumonia, or evidence of active interstitial pneumonia on chest CT during the pre-screening period; Known history of idiopathic pulmonary fibrosis, history of organizing pneumonia (such as bronchiolitis obliterans or cryptogenic organizing pneumonia); and subjects who may interfere with the detection or management of suspected drug-related pulmonary toxicity
* Severe infection (such as intravenous infusion of antibiotics, antifungal or antiviral drugs required according to clinical diagnosis and treatment standards) within 28 days before starting study treatment, or active infection that has received therapeutic intravenous or oral antibiotics within 14 days before starting study treatment
* Known allergy to the study drug or any of its excipients, or history of severe allergic reactions to other vaccines
* Subject has a history of other malignancies within the past 5 years or at the same time, excluding cured carcinoma in situ of the cervix, basal cell carcinoma of the skin or squamous cell carcinoma of the skin, localized prostate cancer after radical resection, ductal carcinoma in situ after radical resection (hormonal therapy for non-metastatic prostate cancer or breast cancer is allowed), and papillary thyroid carcinoma
* Known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation
* Patients with congenital or acquired immunodeficiency, such as cellular immunodeficiency (e.g., DiGeorge syndrome, T-negative severe combined immunodeficiency \[SSCID\]) or combined T-cell and B-cell immunodeficiency (e.g., T- and B-negative combined immunodeficiency, Wiskott-Aldrich syndrome, ataxia telangiectasia, common variable immunodeficiency); or human immunodeficiency virus (HIV) infection
* Active hepatitis B (defined as a positive active hepatitis B virus surface antigen \[HBsAg\] test result during the screening period with detection of HBV DNA ≥500IU/mL or above the upper limit of normal for the study center), or hepatitis C (defined as a positive hepatitis C antibody \[HCV-Ab\] test result and HCV-RNA positive during the screening period)
* Has poorly controlled or severe cardiovascular disease, such as severe/unstable angina, symptomatic congestive heart failure (NYHA Class III. or IV.), myocardial infarction within 6 months prior to initiation of study treatment, or unstable angina pectoris within 1 month prior to initiation of study treatment, or presence of cardiac arrhythmias requiring treatment or intervention, or poorly controlled hypertension (systolic blood pressure ≥ 150mmHg, diastolic blood pressure ≥90mmHg) after adequate treatment
* In the opinion of the investigator, the subject has a history of other serious systemic diseases, or other reasons are not suitable for participating in this clinical study (such as any other disease that may affect the subject's compliance with the study treatment, interfere with the interpretation of the study results, or expose the subject to safety risks, or the tumor tissue sequencing data analysis results show that there are not enough neoantigens available for vaccine preparation, or the vaccine preparation fails); Other circumstances judged by the investigator that may affect the conduct of clinical research and the judgment of research results
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shanghai Regenelead Therapies Co., Ltd.
INDUSTRY
Guangdong Provincial People's Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Wenzhao Zhong, MD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NSCLC-IIT-RGL
Identifier Type: -
Identifier Source: org_study_id